<DOC>
	<DOC>NCT02323867</DOC>
	<brief_summary>This is a single arm pilot study for patients using α/β T cell-depleted PSCT in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and GVHD, and one year leukemia free survival.</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1. Leukemias/lymphomas Acute myeloid leukemia, primary or secondary Disease status: remission or &lt;10% bone marrow blasts Myelodysplasia Acute lymphoblastic leukemia Disease status: in hematologic remission Chronic myelogenous leukemia Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase. Mixed lineage or biphenotypic acute leukemia Lymphoblastic lymphoma Disease status: remission Burkitt's lymphoma/leukemia: Disease status in remission 2. Acceptable organ status clearance 3. No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate antifungal antibiotics and be asymptomatic 4. Signed informed consent. 5. Negative pregnancy test for females of childbearing potential. 1. Patients who do not meet disease, organ or infectious criteria. 2. No suitable donor Donor must be either unrelated, mismatched up to one antigen/one antigen and one allele or a related, HLA match other than a sibling.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Alternative Donor</keyword>
</DOC>